European rare disease biotech Azafaros grabs $28M early funding round

Azafaros has grabbed €25 million ($27.5 million) in a series A investment boost as it looks to push on with its pipeline focused on rare metabolic disorders.

The financing round for the two-year-old biotech was led by Forbion, with extra cash coming from BioMedPartners and founding investor BioGeneration Ventures.